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Consensus Nomenclature for Reporting
Neovascular Age-Related Macular
Degeneration Data
Consensus on Neovascular Age-Related Macular
Degeneration Nomenclature Study Group
Richard F. Spaide, MD,1 Glenn J. Jaffe, MD,2 David Sarraf, MD,3 K. Bailey Freund, MD,1
Srinivas R. Sadda, MD,3 Giovanni Staurenghi, MD,4 Nadia K. Waheed, MD, MPH,5
Usha Chakravarthy, FRCOphth, PhD,6 Philip J. Rosenfeld, MD, PhD,7 Frank G. Holz, MD,8 Eric H. Souied, MD,9
Salomon Y. Cohen, MD,10 Giuseppe Querques, MD,11 Kyoko Ohno-Matsui, MD, PhD,12 David Boyer, MD,13
Alain Gaudric, MD,14 Barbara Blodi, MD,15 Caroline R. Baumal, MD,5 Xiaoxin Li, MD,16
Gabriel J. Coscas, MD,17 Alexander Brucker, MD,18 Lawrence Singerman, MD,19 Phil Luthert, MD,20
Steffen Schmitz-Valckenberg, MD,8 Ursula Schmidt-Erfurth, MD,21 Hans E. Grossniklaus, MD, MBA,22
David J. Wilson, MD,23 Robyn Guymer, MD, PhD,24 Lawrence A. Yannuzzi, MD,1 Emily Y. Chew, MD,25
Karl Csaky, MD,26 Jordi M. Monés, MD,27 Daniel Pauleikhoff, MD,28 Ramin Tadayoni, MD,14 James Fujimoto, PhD29
Purpose: To establish a process to evaluate and standardize a state-of-the-art nomenclature for reporting
neovascular age-related macular degeneration (AMD) data.
Design: Consensus meeting.
Participants: An international panel of retina specialists, imaging and image reading center experts, and
ocular pathologists.
Methods: During several meetings organized under the auspices of the Macula Society, an international
study group discussed and codiﬁed a set nomenclature framework for classifying the subtypes of neovascular
AMD and associated lesion components.
Main Outcome Measures: A consensus classiﬁcation of neovascular AMD.
Results: The study group created a standardized working deﬁnition of AMD. The components of neovascular
AMD were deﬁned and subclassiﬁed. Disease consequences of macular neovascularization were delineated.
Conclusions: The framework of a consensus nomenclature system, a deﬁnition of AMD, and a delineation of
the subtypes of neovascular AMD were developed. Establishing a uniform set of deﬁnitions will facilitate comparison of diverse patient groups and different studies. The framework presented is modiﬁed and updated readily,
processes that are anticipated to occur on a periodic basis. The study group suggests that the consensus
standards outlined in this article be used in future reported studies of neovascular AMD and clinical
practice. Ophthalmology 2020;127:616-636 ª 2019 by the American Academy of Ophthalmology. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Age-related macular degeneration (AMD) is a disease complex that is associated with a high risk of blinding complications. The manifestations are variable, and many have been
discovered only recently. In 1967, Gass1 provided the ﬁrst
description of many of the pathophysiologic features of
neovascular AMD. A few years later, he showed a link
between drusen and neovascular AMD.2 In 1970, Gass,3 in
his ﬁrst atlas, referred to geographic areas of atrophy, and
in 1976, Blair4 described geographic atrophy of the retinal
pigment epithelium (RPE) that occurred in “senile macular
degeneration,” a former term for AMD. The diagnostic
imaging tests at that time were limited to fundus
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photography and ﬂuorescein angiography, which was a
newly described method to evaluate macular disease. Over
the 5 decades since Gass’s 1967 article,1 many studies
have been performed based on imaging data from various
imaging methods, new and old, and have yielded a wealth
of information.
Each form of imaging is a source of data that may provide
varying amounts of independent information about the structure or physiology of the macula in health and disease and that
shapes the concurrent understanding of the underlying pathophysiologic characteristics. The terminology based on ﬂuorescein angiography, used in most of the literature, does not

ª 2019 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.

https://doi.org/10.1016/j.ophtha.2019.11.004
ISSN 0161-6420/19

Table 1. List of Terms and Deﬁnitions
Term
Age-related macular degeneration
Macular neovascularization
Type 1 MNV
Polypoidal choroidal vasculopathy
Type 2 MNV

Intraretinal ﬂuid

Hemorrhage
Fibrosis
Rip (or tear) of the retinal pigment epithelium
Outer retinal atrophy
Retinal pigment epithelial and outer retinal atrophy

AMD ¼ age-related macular degeneration; MNV ¼ macular neovascularization; PED ¼ pigment epithelial detachment; RPE ¼ retinal pigment epithelium.
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Lipid (hard exudates)
Subretinal hyperreﬂective material
Retinal pigment epithelial detachment



Subretinal ﬂuid

A condition in patients, typically beyond 50 years of age, in which the structure and function of the macula deteriorates. A salient
characteristic is the accumulation of extracellular deposits including subretinal drusenoid deposits, basal linear, and basal laminar deposit.
These eyes may demonstrate neovascularization or atrophy.
Denotes neovascular disease in the macula from many causes. In AMD, the neovascularization may start in the outer retina, and therefore,
the term choroidal neovascularization is not appropriate for the class.
Ingrowth of vessels initially from the choriocapillaris into and within the sub-RPE space. Leads to varying types of PEDs.
A variant of type 1 MNV commonly seen in Asian persons. Indocyanine green angiography imaging shows a branching vascular network
and aneurysmal dilations of varying number at the outer edge of the expanding lesion. The internal structure of the aneurysmal structures,
often termed polyps, is controversial.
Neovascularization that originates from the choroid that traverses Bruch’s membrane and the RPE monolayer and then proliferates in the
subretinal space.
Neovascularization that originates from the retinal circulation, typically the deep capillary plexus, and grows toward the outer retina.
Aberrant connection from the retinal to the choroidal circulation.
Exudation of ﬂuid and serum components from a lesion because of the breakdown of the blooderetinal barrier. Fluorescein angiography is a
common way to detect leakage because in health, the blooderetinal barrier blocks the extravascular egress of ﬂuorescein from vessels.
Leakage in excess of the local capability of removal leading to accumulation of the ﬂuid in retinal thickening and formation of cystoid
spaces. The ﬂuid in the retina may come from retinal vessels or a subretinal source if the external limiting membrane is not intact.
Leakage in excess of the local capability of removal leading to accumulation of the ﬂuid under the retina. The ﬂuid source generally is from
underlying neovascularization in AMD in the context of an intact external limiting membrane.
Lipoprotein particles that precipitate in the retina related to chronic vascular leakage.
Exudation into the subretinal space of material likely comprising serum, ﬁbrin, and inﬂammatory cells.
A clinically evident separation of the RPE monolayer from the underlying Bruch’s membrane. This can occur from drusenoid material,
serous ﬂuid, neovascular inﬁltration, or blood. Collections of drusen material of more than 350 mm in diameter are called drusenoid PEDs.
Serous PEDs are collections of ﬂuid, but in AMD, serous PEDs typically are associated with neighboring MNV. Neovascular inﬁltration
usually is associated with some element of ﬁbrotic tissue and are called ﬁbrovascular PEDs. Elevations with blood are called hemorrhagic
PEDs.
Extravasation of blood from the neovascular complex located in the sub-RPE, subretinal, intraretinal, or occasionally, preretinal
compartments.
Buildup, in any layers of the retina, the subretinal space, the RPE monolayer, or the sub-RPE space, of tissue with signiﬁcant collagen
deposition.
Disruption with scrolling and contracture of the RPE monolayer, usually occurring in association with a ﬁbrovascular PED, but on rare
occasions with a serous PED. For ﬁbrovascular PEDs, the sub-RPE proliferation is thought to contract because of the angioﬁbrotic switch,
and the tensile force created leads to the rip.
Loss of the ellipsoid and interdigitation zones usually with corresponding loss of thickness of the outer nuclear layer. Outer retinal atrophy
most commonly occurs after prolonged subretinal ﬂuid accumulation, regression of ﬁeld of subretinal drusenoid deposit, or over large
collections of drusen material.
Atrophy refers to absence of a clinically normal RPE monolayer, usually by cell death. Therefore, it is not really atrophy, which implies a
withering, but rather persistence of cells. In OCT imaging, RPE atrophy is characterized by a loss of the RPE band with associated
choroidal hypertransmission. The loss of RPE cells usually is accompanied by concomitant loss of the outer retina. This combination
forms RPE and outer retinal atrophy. If the zone of abnormalities is more than 250 mm in diameter, then the condition is termed
complete RPE and outer retinal atrophy. If the zone of abnormalities is less than 250 mm, or if the hypertransmisssion is fragmentary, the
eye is said to have incomplete RPE and outer retinal atrophy.
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Type 3 MNV
Retinal-choroidal anastomosis
Leakage

Deﬁnition
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Table 2. New versus Old Terminology Correlates
Old Term
Type 1 MNV

Polypoidal choroidal vasculopathy

Mixed type 1 and type 2 MNV

Type 3 MNV

Retinal-choroidal anastomosis

Leakage
Intraretinal ﬂuid

Type 1 MNV represents areas of neovascular complexes
arising from the choroid and imaged with OCT as an
elevation of the RPE by material with heterogeneous
reﬂectivity; vascular elements may be seen. OCT
angiography shows vessels below the level of the RPE.
OCT ﬁndings similar to type 1 MNV; however, in some
patients, dilated vascular elements at the outer border
of the lesion are apparent. Stippled hyperﬂuorescence
over an area of elevated RPE, which expands to
coalesce in the later phases of the angiography. The
pattern of the RPE elevation may suggest nodules.
Indocyanine green angiography shows a branching
vascular network with aneurysmal dilations.
Neovascular complex located in the subretinal space,
above the level of the RPE. May be associated with
subretinal hyperreﬂective material and separation of
the neurosensory retina from the RPE. OCT
angiography demonstrates vascular elements above
the level of the RPE.
OCT ﬁndings of both type 1 and type 2 MNV together.
OCT angiography demonstrates neovascularization in
the sub-retinal pigment epithelial and subretinal
compartments.
Extension of hyperreﬂectivity from the middle retina
toward to level of the RPE associated with intraretinal
edema, hemorrhage, and telangiectasis. OCT
angiography shows the downgrowth of new vessels
toward or even penetrating the level of the RPE.
Aberrant connection from the retinal to the choroidal
circulation. Course of vessel can be seen occasionally
with OCT or OCT angiography. Although visible on
ﬂuorescein angiography, indocyanine green
angiography often is better at demonstrating the
anastomosis.
Breakdown of the blooderetinal barrier, typically
demonstrated by ﬂuorescein angiography.
Cystoid spaces in the retina typically associated with
increased retinal thickening. Readily detected using
OCT.

Old Term
Occult CNV

Stippled hyperﬂuorescence over an area of elevated
RPE, which expands to coalesce in the later phases of
the angiography.

Polypoidal choroidal vasculopathy

Stippled hyperﬂuorescence over an area of elevated RPE
that expands to coalesce in the later phases of the
angiography. The pattern of the RPE elevation may
suggest nodules. Indocyanine green angiography
shows a branching vascular network with aneurysmal
dilations.

Classic CNV

Early hyperﬂuorescence and late leakage that pools in
the subretinal space. Neovascular elements may be
detected in the very early phase of the angiogram.

Minimally classic CNV

Early hyperﬂuorescence with late leakage and a larger
surround of stippled hyperﬂuorescence that also shows
leakage late in the ﬂuorescein angiogram. Difﬁcult to
differentiate from type 3 neovascularization.
Focal hyperﬂuorescence associated with intraretinal
staining. Often shows ﬂuorescence from deeper layers
suggestive of occult CNV. The neovascularization is
not necessarily CNV.

Retinal angiomatous proliferation

Retinal-choroidal anastomosis

Aberrant connection from the retinal to the choroidal
circulation. Although visible on ﬂuorescein
angiography, indocyanine green angiography often is
better at demonstrating the anastomosis.

Leakage

Breakdown of the bloode retinal barrier, typically
demonstrated by ﬂuorescein angiography.
Thickening of the retina that may be difﬁcult to detect
and cystoid spaces that also may be difﬁcult to detect
by color photography. Fluorescein angiography shows
pooling of dye in some of the cystoid spaces.
Exaggerated accumulations in the macula may be
detected with stereo color photography and also may
be suggested by a loss of transparency of the detached
retina.
Yellow-white globular material in or under the retina.

Cystoid edema

Subretinal ﬂuid

Separation of the neurosensory retina from the RPE by
ﬂuid. Readily detected using OCT.

Subretinal ﬂuid

Lipid (hard exudates)

Yellow-white globular material in or under the retina.
OCT shows hyperreﬂective foci in the retina, some of
which are not visible by ophthalmoscopy.
Exudation in the subretinal space of material that is
hyperreﬂective as compared with ﬂuid.

Lipid (hard exudates)

Subretinal hyperreﬂective material

Color Fundus and Fluorescein Imaging Findings

Not named before OCT era

In extreme cases, material is seen on color photography
that is difﬁcult to differentiate from ﬁbrosis.
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Type 2 MNV

Multimodal Imaging Correlate

Table 2. (Continued.)
Old Term
Retinal PED

Hemorrhage
Fibrosis

Retinal PED

Several forms of elevation of the RPE monolayer from
the underlying Bruch’s membrane. These include
drusenoid, serous, and ﬁbrovascular. Accurately
delineating serous and ﬁbrovascular PEDs can be
difﬁcult. Early type 1 MNV with RPE elevation may
not be detectable.

Hemorrhage

Blood in the retina, subretinal, or sub-RPE
compartments. Location of blood can be inferred.

Fibrosis

White or yellow-white accumulation of material, usually
in the subretinal or sub-RPE space.

Rip (or tear) of the RPE

Area of increased pigmentation from the scrolled RPE
adjacent to a zone of decreased pigmentation. During
ﬂuorescein angiography, the increased pigmentation
blocks the underlying ﬂuorescence, whereas the area
denuded of RPE is hyperﬂuorescent.

Not named before OCT era

No color photograph or ﬂuorescein angiography
correlate.

Roughly correlates to geographic atrophy

The color photographic deﬁnition of geographic atrophy
includes a round or oval well-deﬁned area in which
the underlying choroidal vessels are seen more easily.
In neovascular cases, there is no reason the RPE loss
must be round or oval and well deﬁned. The presence
of underlying neovascular lesion may block
visualization of the choroidal vessels in any case.

CNV ¼ choroidal neovascularization; MNV ¼ macular neovascularization; PED ¼ pigment epithelial detachment; RPE ¼ retinal pigment epithelium.
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RPE and outer retinal atrophy

Color Fundus and Fluorescein Imaging Findings



Outer retinal atrophy

Several forms of elevation of the RPE monolayer from
the underlying Bruch’s membrane. This includes
drusenoid, serous, and ﬁbrovascular. Some forms of
early type 1 neovascularization produce a relatively
ﬂat elevation. Many cases of serous PED show
evidence of MNV. OCT angiography is particularly
useful in detecting the presence of neovascularization.
Blood in the retina, subretinal, or sub-RPE
compartments. Exact location of blood apparent in
OCT examination.
White or yellow-white accumulation of material, usually
in the subretinal or sub-RPE space. on OCT, the
material is hyperreﬂective and may have a
multilaminar appearance.
Area of increased pigmentation from the scrolled RPE
adjacent to a zone of decreased pigmentation. During
ﬂuorescein angiography, the increased pigmentation
blocks the underlying ﬂuorescence, whereas the area
denuded of RPE is hyperﬂuorescent. OCT shows the
anatomic conﬁguration of the scrolled RPE and
hypertransmission in the denuded zone.
On OCT imaging, loss of the ellipsoid and
interdigitation zones associated with thinning of the
outer nuclear layer.
OCT features of outer retinal atrophy and signs of RPE
loss to include decrease or absence of the RPE
monolayer and hypertransmission into the underlying
neovascular lesion and choroid.

Old Term

Spaide et al

Rip (or tear) of the RPE

Multimodal Imaging Correlate
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Figure 1. Electron microscopic image showing the retinal pigment epithelium (RPE) and Bruch’s membrane (BRUCHS). The basal laminar deposit
(BLamD) is located between the plasma membrane (pm) of the RPE and the basement membrane (bm). Between the basal lamina and the trilaminar
Bruch’s membrane is a collection of basal linear deposit (1500).

apply to many aspects of the new data obtained by state-of-theart imaging. Although using multiple imaging methods contributes different viewpoints on macular pathologic features,5
this expanded capability can give rise to a fractured
conceptualization of disease with the potential for varied
terminology. Developing a standardized nomenclature
system would improve clarity and accuracy of
communication and enhance comparability of research
results from different centers using diverse imaging
methods. To develop a better nomenclature to describe
disease, it is necessary to improve the clarity of concepts
involved and evaluate these concepts regarding multimodal
imaging and known histopathologic characteristics.
Nomenclature systems have been developed by hundreds
of organizations and ad hoc working groups to describe
disease and treatment, including standardized nomenclature
of medicine for clinical terms,6 bone density,7 bipolar
disorders,8 radiation therapy,9 nursing diagnoses,10 and
medical documentation.11 In ophthalmology efforts have
been undertaken to standardize the nomenclature of
trauma,12,13 uveitis,14 and anatomic labeling of OCT.15
Age-related macular degeneration is a leading cause of
irreversible visual impairment despite landmark advances,
such as the injection of antievascular endothelial growth
factor (VEGF) agents for macular neovascularization (MNV),
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a term recognizing that neovascularization does not necessarily originate from the choroid.16e19 As the population
continues to age, the incident cases of neovascular AMD are
projected to rise. As in other ﬁelds, AMD could beneﬁt from
standardization of nomenclature that integrates concepts
informed by recent advances in imaging technology. Given the
rapid rate of change in AMD knowledge, any nomenclature
system is likely to be a work in need of periodic revision. To
work toward a consensus, a series of group meetings of experts
were held under the auspices of the Macula Society. The
participants were an international group of retinal specialists,
imaging experts, and ocular pathologists.

Methods
Formation of the Classiﬁcation of Macular
Neovascularization Group
An international team of experts in AMD and AMD imaging
research was assembled to address the deﬁnitions and classiﬁcation
of atrophy in the setting of AMD. The Classiﬁcation of Atrophy
Meetings group was selected by 3 chairs (S.R.S., G.S., and F.G.H.)
using criteria that included a history of relevant publications, recent
AMD and imaging research contributions, a track record of success
in previous collaborative, consensus efforts, and availability to attend
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Figure 2. Light microscopy images showing drusen. A, A solitary druse and
thick layer of basal laminar deposit (BLamD). Although drusenoid deposits
are visible by ophthalmoscopy, BLamD is not typically recognized in the
clinic. B, Conﬂuent soft drusen, which are accumulations of BLamD, are
clinically evident (toluidine blue, 100).

the meetings.20e22 An extension of this meeting addressing MNV
was organized with the addition of 1 additional chair (R.F.S.) in
conjunction with the Macula Society and the Federation France
Macula. The study group, referred to as the Consensus on Neovascular AMD Nomenclature (CONAN) group, comprised an international panel of retina experts with an extensive publication history
in neovascular AMD, representatives of retinal reading centers that
have participated in major trials in AMD, and ocular pathologists
with a considerable history of neovascular AMD publications.
To start the process, an international working group conducted
several meetings to establish the range of concepts pertinent to
OCT angiography, particularly the limitations of current imaging
methods. The meetings were also attended by imaging scientists
from the OCT industry (Heidelberg Engineering, Inc, Franklin,
MA; Optovue Inc, Fremont, CA; Topcon Medical Systems, Inc,
Oakland, NJ; and Carl Zeiss Meditec, Inc, Dublin, CA) who jointly
served as a resource on imaging technologies and their limitations
but did not have any inﬂuence on the outcome of the deliberations.
For the present article, the group prepared preliminary deﬁnitions
of various disease states before the meeting. Initially, these components were introduced in prepared presentations, which were
followed by discussion. From those discussions, a series of schematic drawings of MNV were prepared and distributed for independent grading by the working group members. Initial
examination of the responses from experts of this set of schematic
images of MNV yielded nearly complete disagreement in terminology. Extensive group discussions were followed by the formation of small groups, each charged with developing deﬁnitions
for a subset of entities. These deﬁnitions were then presented to the

Figure 3. Light microscopy images showing neovascularization arising from the choroid. A, Neovascularization in this case proliferates in the potential space
under the basal laminar deposit (BlamD) above the trilaminar Bruch’s membrane. B, The ingrowth site is evident as a defect in Bruch’s membrane (arrow)
(hematoxylin and eosin, 250).
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Figure 4. Diagram showing type 1 macular neovascularization. The ingrowth of vessels arises from the choriocapillaris and extends up to and under the
retinal pigment epithelium.

larger group and then reﬁned by the group at large until consensus
was reached. Additional consultation was obtained from reading
centers and authors outside of the meeting group. Deﬁnitions for
atrophy in the context of neovascular AMD were developed
because these lesions are common.

Results
Consensus Deﬁnitions
A list of deﬁnitions is shown in Table 1. A comparison of the new
terms with older terms developed during the ﬂuorescein
angiography era is shown in Table 2. No direct porting of the
new terms to the old ones and vice versa exists because newer
imaging technologies, such as OCT and OCT angiography, have
an ability to detect abnormalities not imaged by color fundus
photography or ﬂuorescein angiography and have greater
precision for many entities that are imaged using these
technologies. Using OCT and OCT angiography does not replace
ﬂuorescein angiography or color photography; rather, these
additional forms of imaging augment those forms of imaging and
provide additional data to improve classiﬁcation possibilities.
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Age-related macular degeneration is a process by which the
structure and function of the macula deteriorates over time in association with distinguishing signs and symptoms that typically become
evident clinically beyond 50 years of age and do not seem to be
secondary to other processes such as pathologic myopia, central serous chorioretinopathy, monogenetic inherited retinal disease, chorioretinal uveitic syndromes or infections, or trauma. The salient
characteristic of AMD is the accumulation of extracellular deposits
within the macula. Basal laminar deposits are located between the
RPE cell’s plasma membrane and its basal lamina (Fig 1). Basal linear
deposits are located external to the RPE basal lamina (also known as
the lamina densa, as identiﬁed by electron microscopy). Both types of
deposit occur internal to the inner collagenous layer of the trilaminar
Bruch’s membrane. Diffuse thickenings of these deposits may not be
detectable by conventional ophthalmoscopy, but mounds of basal
linear deposit appear as soft drusen (Fig 2).23 Subretinal drusenoid
deposits are accumulations of material located above the RPE and
appear as pseudodrusen. Associated with the extracellular deposits
are morphologic changes in the RPE visible by histopathologic
analysis and, in more advanced stages, clinical imaging.
In the early phases of AMD, the visual performance may show
minimal changes. With time, vitelliform deposit may accumulate,
pigment may migrate into the retina, drusen size may increase, and
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Figure 5. Images showing type 1 macular neovascularization. A, Fundus photograph from a 78-year-old with hemorrhage in the nasal macula. B, Fluorescein
angiography image showing blocking defect caused by the hemorrhage, subtle diffuse leakage (arrow), and punctate leakage (arrowheads). C, OCT image
(top) demonstrating heterogeneous reﬂectivity in a ﬁbrovascular pigment epithelial detachment and (bottom) OCT angiographic overlay showing ﬂow
within the pigment epithelial elevation. D, En face OCT image showing the neovascular network (arrow) and the center of the fovea (asterisk).

hypopigmentation and hyperpigmentation of the RPE may develop.
Late phases of the disease include atrophy of the outer retina,
thinning and loss of the RPE, and MNV (Fig 3). Neovascular disease
can lead to leakage, bleeding, and scarring as well as severe vision
loss. Age-related macular degeneration can be asymmetrical; one
eye may show manifestations, such as drusen, in the absence of
fellow-eye abnormalities. The risk for progression in the eye without
AMD stigmata is nearly zero, and accordingly, one should not diagnose AMD in an eye without visible abnormalities. This raises a
conundrum: should AMD be diagnosed per eye or per patient? The
group elected to consider AMD a disease diagnosed per patient
given the use of vitamin supplements and other measures to reduce
risk are deployed on a per patient basis.

Neovascularization Subtypes
Macular neovascularization is an invasion by vascular and associated tissues into the outer retina, subretinal space, or sub-RPE
space in varying combinations. The ingrowth of neovascularization is generally considered to be pathologic but may
have some beneﬁcial secondary effects as well, in that the neovascularization may be an ocular protective response whereby the
choriocapillaris is recapitulated to improve a deﬁcient oxygen and
nutrient supply.24 The anatomic location of the neovascularization
determined by OCT imaging is used to subclassify the vascular
component of the disease process.

Type 1 Macular Neovascularization. Type 1 MNV is an
ingrowth of vessels initially from the choriocapillaris into the subRPE space (Fig 4). With growth and expansion of the lesion,
remodeling and enlargement of the feeding and draining vessels
occurs within both the choroid and the lesion.25 Accompanying
the ingrowth is a varying amount of additional cellular elements
including ﬁbroblasts, myoﬁbroblasts, and macrophages that seem
to participate in the disease process and can lead to formation of
ﬁbrotic tissue. With ﬂuorescein angiography, type 1 MNV
commonly displays ill-deﬁned regions of multipunctate leakage
that correspond topographically to a region of elevated RPE (i.e.,
stippled hyperﬂuorescence) and thus was termed occult neovascularization (Fig 5). Indocyanine green angiography may help
to visualize some of the vascular structure but often shows just
late staining of the lesion, referred to as a plaque.26 OCT
angiography may aid in the visualization of these lesions.
Leakage from vessels, hemorrhage, or associated proliferation of
ﬁbrotic tissue can cause expansion of a ﬁbrovascular pigment
epithelial detachment (PED). The relative role of the induced
curvature of the pigment epithelium and other biological
alterations on the outer blooderetinal barrier is not yet fully understood. However, in many eyes, increased intralesional hydrostatic pressure coupled with breakdown of the outer blooderetinal
barrier leads to exudation into the subretinal space. Intraretinal
ﬂuid accumulation may occur in conjunction with breakdown of
the external limiting membrane, or VEGF expression may induce
intraretinal leakage independently.27
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Figure 6. Images showing polypoidal choroidal vasculopathy (also known as aneurysmal type 1 macular neovascularization). A, Color photograph showing
extensive exudation with subretinal lipid and an epiretinal membrane. B, Fluorescein angiogram showing hyperﬂuorescence in the region of neovascularization and adjacent dye pooling within a pigment epithelial detachment. C, Indocyanine green angiogram showing hyperﬂuorescent dilations,
which are interconnected by a branching vascular network, some of which are seen. D, Structural OCT showing a nodular vascular structure (arrow) buried
in hyperreﬂective exudative material and an adjacent detachment of the pigment epithelium. E, En face slab structural OCT showing the elevations caused
by aneurysmal aggregates (arrows). F, OCT angiogram showing ﬂow within the RPE elevations with some suggestion of the aneurysmal dilations, but there
are internal details present that suggest tightly entangled vascular elements. RPE ¼ retinal pigment epithelium.

In 1973, Sarks28 reported histopathologic results of eyes with what
is now known as type 1 MNV. These patients showed no clinical signs
of neovascularization. In 1987, Gass29 proposed that patients can
demonstrate an occult stage of disease (not the same as occult type of
neovascularization) in which “the patient is asymptomatic and the
new vessels may not be apparent either ophthalmoscopically or
angiographically.” With the development of indocyanine green
angiography, neovascular plaques with no signs of exudative disease
were discovered in fellow eyes harboring soft drusen.30 Patients with
these nonexudative neovascular plaques had a much higher risk of
progressing to exudative manifestations than eyes without
nonexudative plaques. In 2012, Amissah-Arthur et al31 found OCT
evidence of neovascularization in 88% of eyes before the
development of exudation, with conversion occurring up to 35.5
months after initial entry in the study. After this report, Querques
et al32 in 2013 reported cases of neovascularization without
exudation in separate examinations separated by 6 months or more
and called this form quiescent neovascularization. In 2018, de
Oliveira Dias et al33 reported eyes with nonexudative MNV in sweptsource OCT angiographic imaging had a much higher risk of progressing to exudative manifestations than those without manifestations
of nonexudative MNV. The CONAN group recognizes nonexudative
MNV and that this form of neovascularization could be identiﬁed more
commonly with advances in imaging technology. The group could not
come to a consensus that the designation quiescent was a needed term.
Polypoidal Choroidal Vasculopathy. Polypoidal choroidal vasculopathy34 is an important subtype of neovascularization deﬁned by a
branching vascular network and nodular vascular agglomerations
(Fig 6), also called polyps. Although a minority subtype in white
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populations, it accounts for approximately half of MNV seen in
Asia.35,36 In polypoidal choroidal vasculopathy, the branching
vascular network may have ophthalmologically visible large vessels
(Fig 7), some that can be as large as the retinal arcade vessels. At the
outer border of the vascular lesion, nodular vascular elements can be
present that suggest the appearance of aneurysms. The morphologic
features of the vascular lesion is imaged best with indocyanine green
angiography37 and OCT angiography. In the earlier phases of the
indocyanine green angiographic sequence, the branching vascular
network ﬁlls, and next, the dilatations are imaged. Over time, the dye
is removed from the circulation and late staining of tissue around the
dilatations occurs. Polypoidal choroidal vasculopathy expands
slowly in the sub-RPE space over time and may grow to considerable size before having any meaningful impact on vision. The polyps
may be pulsatile and are particularly prone to bleed. In OCT angiographic imaging, the aneurysmal dilations may not be imaged, suggesting the ﬂow in these lesions is less than the detection limit for this
method of imaging, but the branching vascular network is otherwise
imaged. In Asian persons, the typical presentation comprises isolated
macular involvement, unilateral, and male preponderance, whereas in
white persons, bilateral involvement, female preponderance, and the
neovascular lesion originating from the peripapillary region are more
common.38 Because of the slow perfusion dynamics, most polyps
remain undetected by OCT angiography.
When polypoidal choroidal vasculopathy was named, the lesion
was thought to be a distribution of abnormally dilated choroidal
vessels bordered by enlargements called polyps. Shortly thereafter,
separate histopathologic reports established that the lesion was the
growth of cavernous thin-walled vessels immediately external to
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the RPE,39e41 above Bruch’s membrane. The word polyp ordinarily refers to either a sedentary aquatic invertebrate or a solid
growth of tissue from a mucous membrane, and not a vascular
abnormality. Thus, every word of the term polypoidal choroidal
vasculopathy is incorrect. An alternate term, aneurysmal type 1
neovascularization, has been proposed, but consensus could not be
reached regarding whether polyps were simple aneurysms or more
complicated vascular structures.42
Type 2 Macular Neovascularization. Type 2 MNV refers to the
proliferation of new vessels arising from the choroid into the subretinal space (Fig 8). Although these vessels traverse the sub-RPE
space, the disease process in type 2 neovascularization is dominated by the subretinal portion (Fig 9). These lesion types are
associated with exudation or hemorrhage directly into the
subretinal space. Type 2 neovascularization may be a component
of a larger process including other forms of neovascularization in
varying amounts. Type 2 lesions have the ﬂuorescein angiographic
characteristics of early, typically well-deﬁned hyperﬂuorescence
with late leakage. OCT angiography shows a neovascular network
above the level of the RPE. Type 2 MNV occurs in conditions other
than AMD that affect the RPE, such as angioid streaks, lacquer
cracks, and chorioretinitis.
Type 3 Macular Neovascularization. Type 3 MNV refers to a
downgrowth of vessels from the retinal circulation toward the
outer retina. Thus, the term choroidal neovascularization is not
accurate for type 3 neovascularization. The vascular proliferation
is suspected to start from the deep capillary plexus in the retina
with the vector of growth extending toward the outer retina.
Increasing blood ﬂow within the angiomatous proliferation is
supplied by the retinal vessels, which seem to remodel over time to
handle the ﬂow requirements (Figs 10 and 11). Scattered ﬂecks of
intraretinal hemorrhage (always outside the foveal avascular zone)
and cystoid spaces are present, both of which may appear before
the neovascularization. The neovascularization has the potential
to leak and bleed. Fluorescein angiography demonstrates
intraretinal leakage of ﬂuorescein with potential for cystoid
macular edema, which can be substantial (Figs 12 and 13).
Indocyanine green angiography shows a small hyperﬂuorescent
lesion, which likely represents descending vessels viewed
axially. OCT shows varying amounts of intraretinal edema,
which in some eyes can be widespread compared with any
neovascularization
present.
OCT
angiography
shows
proliferation of vessels into the deeper portions of the retina;
although these vessels seem to originate from the deep vascular
plexus, with increasing proliferation and ﬂow, remodeling of the
vessels supplying and draining the neovascularization occurs.
The eyes may also show subretinal ﬂuid and exudation,
subsidence of the retina, and development of a PED, ﬁndings
highlighted by available histopathologic results (Fig 14).
Proliferation to the level of the RPE and eventual breakthrough
of this layer can lead to sub-RPE neovascularization with potential
for anastomosis to deeper layers. Although both type 2 and type 3
neovascularization lead to new vessels in the subretinal space, type
3 neovascularization originates from the retinal microvasculature,
whereas types 2 and 1 develop from the choroid. Earlier descriptions of this form of neovascularization varied in content and
used terms including retinal vascular anomalous complexes,43
retinal angiomatous proliferation (also known as RAP),44 and
occult retinal choroidal anastomosis.45
Retinal-Choroidal Anastomosis. An anastomosis is a vascular
communication between channels that are not ordinarily connected
by means of vessels typically larger than a capillary. These vessels
are a conduit for blood ﬂow through neovascular networks that
allows blood ﬂow either from the retina to the choroid or the
opposite, depending on relative pressure differences. The CONAN
group recommends that the lesion should be named retinal-

Figure 7. Light microscopy images showing polypoidal choroidal vasculopathy. A, A large lesion with subretinal and suberetinal pigment epithelium
hemorrhage (hematoxylin and eosin, 100). B, Area shown in the bounding
box in (A). Note the large thin-walled neovascular vessel (arrow) ﬂanked by
intralesional hemorrhage (arrowheads) (hematoxylin and eosin, 200).

choroidal anastomosis, consistent with a retina-to-choroid hierarchical naming strategy that does not refer to the directionality of
blood ﬂow. Retinal-choroidal anastomoses are detected commonly
using dye-based angiography, although OCT and OCT angiography may prove sufﬁcient.
Neovascular Lesion Nomenclature. Based on the foregoing
descriptions, the CONAN group proposes that the following terms
should be used. Type 3 neovascularization is to be used when the
vascular complex originates in the retina. Type 1 neovascularization is applied when the vessels originate from the
choroid and remain under the RPE. Type 2 neovascularization is
denoted if neovascularization that originates in the choroid breaks
through the RPE to reach the subretinal space. The term type 2 is
derived from the anatomic location of the proliferating neovascular
frond, although blood ﬂow has to transverse the sub-RPE space to
reach the subretinal space. If prominent neovascularization is
present in the subretinal and sub-RPE compartments, the term
mixed type 1 and type 2 neovascularization can be applied (Fig
15). Comparison of the histopathologic features of type 2 versus
a mixed type 1 and 2 lesion is shown in Figure 16. Patients with
mixed type 1 and type 2 lesions can show apparent regression of
the type 2 component after initiation of treatment.46 An eye with
type 3 disease that has penetrated the RPE monolayer without
making an anastomosis with the choroidal circulation is said to
have extension of the type 3 disease into the sub-RPE space.
Although the extension is under the RPE, it may not have the same
long-term consequences as does type 1. Some evidence exists that

625

Ophthalmology Volume 127, Number 5, May 2020

Figure 8. Diagram showing type 2 macular neovascularization. The ingrowth of vessels arises from the choriocapillaris and extends up through the retinal
pigment epithelium (RPE) monolayer to proliferate in the subretinal space. To arrive in the subretinal space, the blood ﬂow must traverse the sub-RPE space
to reach the plane of neovascularization.

eyes with type 1 disease may be less likely to demonstrate RPE
atrophy47 than other forms of MNV, even with anti-VEGF treatment. Some eyes may show type 3 neovascularization and a
separate unconnected region of another form of neovascularization,
for example type 1 neovascularization. This situation may be
summarized as type 3/1 neovascularization, in which the “/” is
interpreted as meaning “and” in an independent sense.

Exudative Features of Macular
Neovascularization
Exudation is a common feature of MNV and can manifest in 4
basic forms: leakage, subretinal ﬂuid, lipid, and subretinal hyperreﬂective exudative material (SHRM).
Leakage. Leakage is the release of excess ﬂuid and serum
components as the result of the breakdown of the bloodeocular
barrier. Leakage is typically detected with ﬂuorescein angiography, in which hyperﬂuorescence outside of vascular conﬁnes is
seen to expand in area over the course of the angiographic
sequence. The dye may accumulate in tissue, a process called
staining, or into ﬂuid ﬁlled spaces, termed pooling. The
appearance of hyperﬂuorescence does not necessarily mean that
edema is present. It is possible that alteration in tissue function
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associated with local leakage could be present without overt
signs of edema.
Intraretinal and Subretinal Fluid. Intraretinal and subretinal
ﬂuid accumulate if the leakage is in excess of local capability to
remove the ﬂuid. Intraretinal ﬂuid may accumulate from retinal
vasculature leakage or intraretinal neovascularization or diffusion
of ﬂuid through the outer retina related to abnormalities of the
external limiting membrane and associated structures. The accumulation of subretinal ﬂuid is dependent on removal rates; for
example, disturbances in the RPE pump function may contribute to
the buildup of subretinal ﬂuid.
Lipid (or Hard Exudates). Lipid (or hard exudates) are lipoprotein precipitates related to chronic vascular leakage. The
aqueous component of the leakage may be reabsorbed by different
mechanisms that do not remove associated lipoprotein molecules
directly. As such, the concentration of lipoprotein molecules may
exceed their solubility, resulting in tissue deposition.
Subretinal Hyperreﬂective Material. Subretinal hyperreﬂective
material is the exudation into or under the retina of material excluding
red blood cells, as would be detected by color fundus photography.
The material is detected by OCT and appears as regions of featureless
accumulations of relatively uniform increased reﬂectivity. The material may include an admixture of serum, ﬁbrin, and inﬂammatory
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Figure 9. Images showing type 2 neovascularization. A, Fundus photograph from a 74-year-old showing a hyperpigmented ring in the fovea (arrow). B, C,
Early-phase ﬂuorescein angiogram showing (B) a well-deﬁned lesion with late leakage and (C) obscuration of the borders of the neovascular lesion. D, Bscan OCT showing the outer retinal lesion with extension of subretinal ﬂuid under the fovea. The ingrowth site through the retinal pigment epithelium is
evident (arrow).

cells. Subretinal hyperreﬂective material is not hyperautoﬂuorescent,
as opposed to vitelliform material, which is hyperautoﬂuorescent.
Subretinal hyperreﬂective material can resolve, but ﬁbrosis can occur
in its wake.48,49 The presence of SHRM is associated with poorer
visual outcomes.48 Patients with type 2 neovascularization
demonstrate exudation directly into the subretinal space. Clues to
the presence of type 2 neovascularization in the context of SHRM
include a classic pattern on ﬂuorescein angiography, disruption of
the external limiting membrane, and intraretinal ﬂuid.
Reappearance of SHRM is a sign of recurrent exudative activity
resulting from neovascularization.50

Lesion Components in Addition to Macular
Neovascularization
Classiﬁcation of the neovascularization concentrates on the topologic features of the new vessel growth but does not describe the
resultant lesion. Additional terms are needed to describe the
associated lesion components. The separation of lesion features
from lesion components is somewhat arbitrary, but historically,
exudation such as lipid or SHRM does not inhibit measurement of
lesion size when imaged using ﬂuorescein angiography. Lesion
components can prevent the proper appreciation of the size of the
neovascular lesion as assessed by ﬂuorescein angiography, and so
were considered to be part of the larger lesion. With the advent of

modern imaging techniques such as OCT angiography, some of
these considerations were obviated.
Retinal Pigment Epithelial Detachment. In AMD, RPE detachments are caused by an elevation of the RPE monolayer and its
basement membrane from the inner collagenous layer of Bruch’s
membrane by sub-RPE ﬂuid, blood, or ﬁbrovascular material.
Serous PEDs may occur in the context of nonneovascular AMD,
but indocyanine green angiography has shown the large majority in
eyes with AMD occur because of neovascularization.51 The RPE
may be elevated by ﬂuid released from the neovascularization,
and this may occur eccentric to the neovascular tissue, producing
a notched PED where the neovascularization is in the notch.
More commonly, the neovascularization is seen adherent to the
undersurface of the RPE and its basal lamina. The structure of a
ﬁbrovascular PED is dominated by vessels and ﬁbrotic tissue in
a complex arrangement, although serous ﬂuid may also be
present. OCT and OCT angiography can be used to detect the
internal anatomic structure of the PED, and OCT angiography
can be particularly effective to image the associated vascular
network, particularly if the PED is shallow. A special class of
PED, drusenoid PED, is a large druse or a conﬂuence of drusen,
with a size at least 350 mm as deﬁned by the Age-Related Eye
Disease Study or at least 433 mm as deﬁned in the Age-Related Eye
Disease Study 2.52,53 Because measurements are typically
performed digitally now, instead of using a standard circular
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Figure 10. Diagram showing initiation of type 3 neovascularization. When the regional proangiogeniceantiangiogenic balances shift in favor of neovascularization, proliferation of vessels occurs along a vector along the vascular endothelial growth factor concentration gradient. The new vessels originate
from and invade into tissues below the plane of the deep capillary plexus. Elevated cytokines, particularly vascular endothelial growth factor levels, can
induce vascular leakage and intraretinal hemorrhage in addition to stimulating angiogenesis. RPE ¼ retinal pigment epithelium.

Figure 11. Images showing type 3 neovascularization. A, Diagram showing proliferation of vessels posteriorly with formation of what has been called an
angiomatous lesion. The vessels supplying the blood ﬂow to the angiomatous proliferation remodel into larger feeding and draining vessels. The edema and
hemorrhage in the retina are from both the neovascularization and to increased local tissue levels of vascular endothelial growth factor. Some evidence is
present that the retinal pigment epithelium monolayer may not be intact, even before penetration of new vessels into the basal laminar or basal linear
material. B, Comparative indocyanine green angiographic image of a patient with an established type 3 neovascular lesion.
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Figure 12. Images showing development of early type 3 macular neovascularization. A, Fundus photograph obtained at baseline showing drusen in the
macular region. The green arrow indicates the location for future B-scan OCT images. B, Early-phase ﬂuorescein angiogram showing decreased early
ﬂuorescence of the central macula. C, Early indocyanine green angiogram showing the decreased early ﬂuorescence of the central macula seen in (B). D,
OCT image showing drusen of varying sizes. E, Fundus photograph obtained 8 months later showing that the patient continued to harbor drusen. F,
Fluorescein angiogram showing a very small dot of hyperﬂuorescence (arrow). G, Indocyanine green angiogram in which the very small dot of hyperﬂuorescence seen in (F) is barely visible. H, OCT image showing increased reﬂectivity in Henle’s ﬁber layer above the solitary larger druse. I, Fundus
photograph obtained 9 months later showing that the patient harbored small hemorrhages (arrows). J, Fluorescein angiogram in which the hyperﬂuorescence
is more evident. K, Indocyanine green angiogram in which the spot seen in (J) also is more evident. L, OCT image showing cystoid spaces within the retina
adjacent to the neovascularization descending to the druse.

measurement, 350 mm would be more convenient.52 Pigment
epithelial detachments can occur in the context of type 1 or type
3 MNV. The association with type 1 may be related to the subRPE location of the vessels and potential exudation. The association with type 3 is harder to explain with current knowledge.
Although outer retinal exudation from the descending neovascularization may overwhelm the ﬂuid diffusion abilities through
Bruch’s membrane, why similar PEDs do not form in the context
of type 2 MNV is not known.
Hemorrhage. Hemorrhage is an extravasation of blood from
the neovascular complex and can be located in the sub-RPE,
subretinal, intraretinal, and occasionally preretinal compartments.
Fresh blood is red and hypoautoﬂuorescent. As blood ages, it becomes yellow, does not stain during ﬂuorescein angiography, and
also is hyperautoﬂuorescent, in contradistinction to ﬁbrosis, which
is not hyperautoﬂuorescent.
Fibrosis. The clinical deﬁnition of ﬁbrosis is based on color
photography and ﬂuorescein angiography and refers to the
apparent build-up of tissue in any layers of the retina, including the
subretinal space, RPE monolayer, or sub-RPE space, of tissue
suspected of harboring signiﬁcant collagen deposition. The ﬁbrotic

region typically stains on ﬂuorescein angiography and is not
hyperautoﬂuorescent in autoﬂuorescence imaging. Fibrosis as
imaged by color photography or ﬂuorescein angiography has an
uncertain OCT correlate at present.54 Fibrotic tissue as seen by
histopathologic examination has not been correlated closely with
the clinical imaging but in histologic specimens contains type 4
collagen deposited by ﬁbroblasts, myoﬁbroblasts, and potentially
transdifferentiated RPE cells and may be a lesion component in
its own right but may be admixed with neovascular tissue.
Fibrosis is a part of the wound-healing response55 that results
from numerous cytokines and factors such as transforming
growth factor b1, pigment epithelial growth factor, and
connective tissue growth factor.56 Fibrotic tissue is associated
with lesion contraction; it has been proposed that a balance
between VEGF and connective tissue growth factor may control
the behavior of ﬁbrovascular tissue. Higher levels of VEGF in
relation to connective tissue growth factor may promote vascular
growth, whereas decreases in the ratio may lead to increased
ﬁbrosis, scarring, and contracture of that tissue.56
Rip. Rip (or tear) of the RPE is caused by a tractional dehiscence of the RPE monolayer. It is theorized that contracture of the

629

Ophthalmology Volume 127, Number 5, May 2020

Figure 13. Images showing type 3 neovascularization with prominent edema and hemorrhage. A, Fundus photograph from an 87-year-old showing dozens of
small ﬂeck hemorrhages in the superior and nasal macula. The blue arrows show the location of the structural OCT scans. B, OCT scan of the section
through the superior arcade showing expansion of the inner nuclear layer (arrowhead) and Henle’s ﬁber layer from edema ﬂuid (arrow). C, OCT scan of the
section through the superior parafovea revealing edema of inner nuclear layer and Henle’s ﬁber layer with cystoid spaces (yellow and green asterisks,
respectively). Hyperreﬂectivity within the retina overlying the apex of the retinal pigment epithelial detachment (arrow) is evident. Note the edema nasal
and temporal to the area of neovascularization is greater than that immediately surrounding the new vessels. D, OCT scan of the inferior macula showing
edematous thickening of the retina and subretinal ﬂuid. E, Fluorescein angiogram showing a small area of hyperﬂuorescence corresponding to the hyperreﬂective area in (C). F, Later ﬂuorescein angiogram showing pooling of dye in cystoid spaces as well as diffuse staining well away from the area highlighted
by the arrow in (E). G, Fundus photograph of magniﬁcation of the central portion of the involved macula showing the numerous isolated hemorrhages,
many of which were in the inner retina. The green arrow shows the section captured by the OCT angiogram in (H). H, OCT angiogram showing the small
focus neovascularization found within the outer retina (open arrow). The vertical double arrow is 150 mm. Note that the hemorrhages do not colocalize with
the neovascularization.

sub-RPE ﬁbrovascular tissue leads to sub-RPE traction across the
inner chord diameter of the RPE detachment.57,58 Tensile forces
greater than the structural strength of the RPE monolayer can
lead to a tear. The contracture of the ﬁbrovascular tissue may be
related to the angioﬁbrotic switch.59 The dehisced RPE
monolayer retracts to a varying extent, producing a heaped-up region adjacent to a zone of absent RPE tissue. The retracted RPE
monolayer causes decreased transmission to the deeper layer. This
causes decreased ﬂuorescence during ﬂuorescein angiography and
choroidal hypotransmission with OCT. It is hyperautoﬂuorescent
because of the increased light path through ﬂuorophores. In contrast,
the area denuded RPE shows hyperﬂuorescence in ﬂuorescein and
indocyanine green angiography and hypertransmission to the
choroid on OCT. With absence of the RPE, and likely atrophy of the
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choriocapillaris, ﬂow signal can be obtained from deeper choroidal
vessels in OCT angiography.

Components of Atrophic Age-Related Macular
Degeneration in the Context of Macular
Neovascularization
The main causes of vision loss in neovascular AMD include those
directly related to the new vessels such as leakage, hemorrhage,
and ﬁbrosis. Another important cause of vision loss, particularly in
treated cases, is atrophy.60 The deﬁnition used in studies of
geographic atrophy, a sharply deﬁned round or oval area of
decreased pigmentation in which the underlying choroidal
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Figure 14. Light microscopy images showing histopathologic analysis of
type 3 neovascularization. A, Entanglement of capillaries in a neovascular
frond extending down through the outer nuclear layer (open arrow) to a
retinal pigment epithelium (RPE) defect. Note the gap in the RPE layer at
the region of contact (double arrow). The choriocapillaris bears numerous
areas absent of vessels, some of which are shown by the black arrows, and
the green arrows highlight deeper vessels that have been enfaced to the
choriocapillaris level (hematoxylin and eosin, 100). B, Higher magniﬁcation of the neovascularization (hematoxylin and eosin, 200).

vessels were more easily seen,61 does not translate well to
neovascular lesions. No foundational reason exists to expect that
the atrophic areas in the context of MNV would be round or oval
well-deﬁned lesions. Because intervening neovascular tissue is present, the underlying choroidal vessels may not be seen at all. In the
Age-Related Eye Disease Study 2, 40% of patients demonstrating
MNV also showed atrophy at baseline.62 These data illustrate how
late AMD is not an either-or phenomenon. Therefore, the CONAN
group followed the lead of the Classiﬁcation of Atrophy Meetings
group20 and adapted their deﬁnitions for nonneovascular AMD to
describe atrophy in the context of neovascular disease.
Outer Retinal Atrophy. Outer retinal atrophy refers to
observable architectural thinning of the outer nuclear layer with
loss of visualization and intensity of reﬂection from outer retinal
bands, particularly the ellipsoid zone as imaged by OCT.63 There
are no correlates visible by color fundus photography because
this imaging method merely provides en face information, unlike
OCT, which allows the architecture of the retinal layers to be

visualized. Outer retinal atrophy can be seen in areas overlying
large drusen, after regression of SDD, over areas of
neovascularization, over areas of ﬁbrosis, and in regions affected
by subretinal ﬂuid. Histologic evaluation has shown loss of
photoreceptor outer segments, retraction and widening of the
inner segments, and loss of the number of nuclei in the outer
nuclear layer.64 In complete outer retinal atrophy (cORA),
the ellipsoid zone and the interdigitation zone are not visible, the
external limiting membrane may not be discernable, and the
outer nuclear layer becomes thinner. In incomplete ORA, a
discontinuous loss of the ellipsoid zone has occurred, and the
interdigitation zone is typically not visible.20
Retinal Pigment Epithelial and Outer Retinal Atrophy. In
complete RPE and outer retinal atrophy,20 an absence of the RPE is
present, as manifested in OCT imaging by a loss of the RPE band
with associated choroidal hypertransmission in OCT imaging,
together with the ﬁndings of cORA in a zone of at least 250 mm
(Fig 17). Incomplete RPE and outer retinal atrophy is deﬁned in
OCT imaging by heterogeneous hypertransmission and
associated fragmentary attenuation or loss in the reﬂectivity from
the RPE band with overlying photoreceptor degeneration in a
zone less than 250 mm. In patients with MNV with exudation or
in treated patients, the extent of RPE loss can be difﬁcult to
determine from OCT scans, because it may be difﬁcult to
identify with certainty the RPE band when adjacent exudation or
ﬁbrosis decreases local contrast. Autoﬂuorescence imaging is
very helpful; a region with decreased or absent autoﬂuorescence
in the absence of overlying hemorrhage implies a loss of
functional RPE cells.
Varying amounts of atrophy are often present in eyes with
MNV. Loss of more central macular tissue leads to the use parafoveal areas for ﬁxation at a cost of decreased visual acuity. Visual acuity is related to the health and proximity that the new
retinal locus of ﬁxation has to the macular center. If parafoveal and
perifoveal atrophy are present, the patient may retain relatively
good visual acuity because the central fovea is intact. Subsequent
involvement of the fovea with neovascularization would compromise foveal function, but then the nearest intact area of the retina to
establish eccentric ﬁxation may be outside of the anatomic conﬁnes
of the macula. In these cases, a small area of neovascularization
may cause a large loss of visual acuity.

Discussion
Advances in diagnostic imaging and learnings from therapeutic outcomes have substantially changed the understanding of neovascular AMD as a morphologic disease
entity. The substitution of largely angiographic deﬁnitions
by OCT-based feature identiﬁcation, the insight into the
origins of neovascular development including both the
retina and choroid, and the differentiation of neovascular
and atrophic pathways including their concomitant occurrence are prominent examples of evolution of disease
conceptualization and the need for adjustment in AMD
terminology. The OCT and OCT angiography ﬁndings, both
noninvasive methods of imaging MNV, do not correspond
directly to the older ﬂuorescein angiographic categories
such as classic, occult, or mixed. Over a period of 3 years,
the CONAN study group held 3 two-day meetings to achieve consensus on many aspects of AMD. Consultation with
outside experts and reading centers was obtained to help
harmonize the deﬁnitions. The proposed classiﬁcation has
been propelled by advances in imaging technology,
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Figure 15. Images showing mixed type 1 and type 2 macular neovascularization. A, Fundus photograph from 62-year-old showing a region of yellowish
exudation (larger arrow). Note the drusen (smaller arrow) and pseudodrusen (arrowhead). B, Early-phase ﬂuorescein angiogram showing a well-deﬁned area
of neovascularization (vertical arrow). C, Later-phase ﬂuorescein angiogram showing pronounced leakage from the well-deﬁned neovascularization and some
punctate leakage from and adjacent area (open arrow). D, En face OCT angiogram showing 2 perspectives: (Top) above the level of the retinal pigment
epithelium (RPE), the well-deﬁned lesion seen in the ﬂuorescein angiogram is evident (vertical arrow); (Bottom) the slab section was deepened to include
visualization of neovascularization below the RPE. The neovascularization above the RPE, seen as the well-deﬁned lesion, is type 2, and the deeper proliferation, below the RPE, is type 2 macular neovascularization.

particularly OCT and OCT angiography, which have provided detailed 3-dimensional analysis of the vascular
anatomic and topographic characteristics within neovascular
AMD lesions. Use of accepted classiﬁcation and terminology will improve standardization of investigation and
reporting of AMD. Better precision in terminology will
enhance reporting and comparability of AMD studies. The
CONAN group recommends that the consensus standards
outlined in this article should be used in future reported
studies of neovascular AMD.
A plethora of terms exist in the literature to describe the
lesions seen in neovascular AMD, and many of these continue
to appear in the current literature. Many of these terms are
based on older imaging technologies. For example, the term
occult neovascularization is a ﬂuorescein angiographic term
describing MNV in which the vessels are not visualized
directly but are rather presumed to be present based on certain
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ﬂuorescein leakage characteristics.65 This ﬂuorescein
angiographic appearance was used to infer that a subtype of
neovascularization was present.66 These ﬂuorescein
angiographic imaging characteristics are the result of
discernable ﬂuorescence within and in tissue around vessels
but are inﬂuenced by many associated nonvascular factors,
including vessel location, pigmentation, permeability of
overlying RPE, and associated hemorrhage and exudation.
OCT and OCT angiography techniques afford direct
imaging of the anatomic features with precision in
evaluating each component, neovascular or not.
Limitations and Challenges for the Future
The classiﬁcation system is based on current knowledge of
neovascularization imaged with contemporaneous imaging
capabilities. Producing the most robust models of visual
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Figure 17. Complete retinal pigment epithelial and outer retinal atrophy in
an eye with type 1 macular neovascularization (MNV) (arrow). Loss of the
outer retina over the ﬁbrovascular pigment epithelial detachment is present.
The ellipsoid termination is demarcated by the arrowheads. Central to this is a
tapering discontinuance of the outer nuclear layer (angled double arrow).
Absence of the underlying retinal pigment epithelium with hypertransmission into the choroid (horizontal double arrow) is present.

Figure 16. Light microscopy images showing variations on neovascularization arising from the choroid. A, The proliferation can occur
directly under the retinal pigment epithelium (RPE). Note that the RPE
and photoreceptors are intact. B, Neovascularization may grow in a purely
subretinal location. The RPE is disrupted, the photoreceptors are atrophic,
and cystoid edema is present. C, A mixed pattern of neovascular proliferation manifesting as both sub-PRE and subretinal growth. The neovascularization is collagenized; this may be considered a disciform scar
(hematoxylin and eosin, 100).

function, disease severity, and prediction for future vision
loss will require additional information from multimodal
imaging and cross-correlation with functional data. New
research will be required to reach these goals. Over time,
knowledge about neovascularization will increase and
associated concepts will be reﬁned. Concurrently, imaging
will improve, and additional biomarkers may be realized.
The current classiﬁcation provides a method to categorize
neovascularization and other lesion components in neovascular AMD and should help to improve standardization
and communication among researchers, clinicians, and patients. This new classiﬁcation should help future studies to
be more rigorous and generalizable. It should also help in
harmonizing deﬁnitions among both reading centers and
clinical investigators. The general framework of this classiﬁcation allows its reﬁnement with the addition of future
data, including analysis of accuracy and repeatability of the
deﬁnitions.
With a classiﬁcation system in place, a method of
grading neovascular AMD disease severity would be
possible. Currently, AMD is typically classiﬁed into stages,
such as early, intermediate, or late.66 The risk of progression
from an earlier stage to late disease was analyzed
extensively from data obtained in the Age-Related Eye
Disease Study and used to create the Beckman

classiﬁcation.67 Late AMD was deﬁned as either geographic
atrophy or choroidal neovascularization. Substituting more
modern terms, late AMD would be complete RPE and
outer retinal atrophy,20 an OCT-deﬁned entity that corresponds roughly to geographic atrophy or MNV. Criticisms
of this approach are that complete RPE and outer retinal
atrophy and MNV are different conditions with dissimilar
pathophysiologies, and therefore, they should not be lumped
together. The basis of this staging system was from an era
when late AMD implied an extraordinary risk for severe
vision impairment. Detecting a neovascular lesion by ﬂuorescein angiography, for instance, generally meant the patient harbored an extreme risk for profound vision loss. The
goal was to predict the likelihood of progressing to late
disease, not to predict visual function. With modern treatment, stabilization or improvement of visual acuity is likely
in patients with MNV, leading to the need to grade disease
severity, which is an assessment of the total effect of disease
on an organ, both reversible and irreversible. The CONAN
group envisions that an extension of proposed terminology
to describe disease severity in neovascular AMD and its
relationship to visual function will be developed.
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